SNYNF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 6.54% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 7.55% beat DBV Technologies SA's return on equity of --.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.28%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 246.92%. Given that DBV Technologies SA has higher upside potential than Sanofi SA, analysts believe DBV Technologies SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.357, which suggesting that the stock is 64.289% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.56%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than DBV Technologies SA quarterly revenues of --. Sanofi SA's net income of $531.9M is higher than DBV Technologies SA's net income of -$23M. Notably, Sanofi SA's price-to-earnings ratio is 20.81x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of 6.54% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 7.55% beat Genfit SA's return on equity of --.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.28%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 213.05%. Given that Genfit SA has higher upside potential than Sanofi SA, analysts believe Genfit SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.357, which suggesting that the stock is 64.289% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.56%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Genfit SA quarterly revenues of --. Sanofi SA's net income of $531.9M is higher than Genfit SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 20.81x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus 5.59x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of 6.54% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 7.55% beat Innate Pharma SA's return on equity of -72.79%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.28%. On the other hand Innate Pharma SA has an analysts' consensus of $8.02 which suggests that it could grow by 338.25%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.357, which suggesting that the stock is 64.289% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.567%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.56%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Innate Pharma SA quarterly revenues of --. Sanofi SA's net income of $531.9M is higher than Innate Pharma SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 20.81x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus 10.94x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.